Localized Unresectable Neuroblastoma Clinical Trial
Official title:
Prognostic Multigene Expression Classification of Neuroblastoma Patients
This research trial studies specimens from young patients with neuroblastoma. Studying the genes expressed in specimens from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PRIMARY OBJECTIVES:
I. Establish a robust messenger ribonucleic acid (mRNA) gene expression classifier for
improved outcome prediction in children with neuroblastoma by using real-time polymerase
chain reaction (PCR) to quantify mRNA levels from genes that have been shown in at least 2
independent studies to have predictive power.
II. Identify microRNA (miRNA) patterns that have prognostic significance in neuroblastoma
(NB) as accumulating evidence indicates that alterations in miRNA expression play a critical
role in tumorigenesis and can be used in prognostic evaluation.
III. To perform an integrated analysis of the established microRNA classifier with our mRNA
signature to determine whether it results in even better classification of NB tumors.
OUTLINE:
Previously collected samples are analyzed for 59 prognostic genes by real-time quantitative
PCR-based gene expression profiling.
;
Observational Model: Case Control, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT01175356 -
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
|
Phase 1 | |
| Active, not recruiting |
NCT00026312 -
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
|
Phase 3 | |
| Recruiting |
NCT00904241 -
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
|
||
| Completed |
NCT00567567 -
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
|
Phase 3 | |
| Completed |
NCT01418495 -
Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
|
||
| Completed |
NCT01358617 -
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma
|
N/A | |
| Completed |
NCT00033293 -
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
|
Phase 3 | |
| Completed |
NCT00898391 -
Study of DNA in Blood Samples From Patients With Neuroblastoma
|
N/A | |
| Completed |
NCT01208454 -
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
|
Phase 1 | |
| Completed |
NCT00028522 -
R(+)XK469 in Treating Patients With Advanced Neuroblastoma
|
Phase 1 | |
| Completed |
NCT00436696 -
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
|
||
| Active, not recruiting |
NCT02176967 -
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
|
Phase 3 |